Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03705533
Recruitment Status : Completed
First Posted : October 15, 2018
Last Update Posted : December 27, 2018
Sponsor:
Collaborator:
Algorithme Pharma, An Altasciences Company
Information provided by (Responsible Party):
Pharmtechnology LLC

Brief Summary:
This single center, randomized, single dose, full replicate, crossover comparative laboratory-blinded study will be conducted in healthy male and female volunteers in order to determine the bioequivalence of two different formulations of telmisartan 80 mg tablets after oral administration under fasting conditions.

Condition or disease Intervention/treatment Phase
Bioequivalence Drug: Telmisartan Drug: Micardis Phase 1

Detailed Description:

The study is characterized by single center, randomized, single dose, laboratory-blinded, 4-period, 2-sequence, full replicate crossover design.The objective is to determine the bioequivalence of two different formulations of telmisartan after a single oral dose administration under fasting conditions. The test product is Telmisartan 80 mg tablets manufactured by Pharmtechnology LLC, Belarus. The reference product is Micardis 80 mg tablets manufactured by Boehringer Ingelheim Ellas AE, Greece. The primary study endpoints are the pharmacokinetic parameters Cmax and AUC0-T of telmisartan.

Eligible 26 healthy adult subjects will be randomized to the one of two predetermined sequences: ABAB or BABA where A = the test product, B = the reference product. Clinical part of the study will include 4 periods; in each of them a single 80 mg dose of telmisartan will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast. Wash-out period between treatment administrations will last at least 14 calendar days.

Subjects will be confined to the clinical site from at least 10 hours prior to each drug administration until 24 hours following each drug administration. Subjects will return to the clinical site for the remaining blood samples.

In each study period, 21 blood samples will be collected for pharmacokinetic assessments. The first blood sample will be collected prior to drug administration while the others will be collected up to 72 hours after drug administration (0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 postdose) .

Total study duration: up to 74 days (including screening).

Telmisartan plasma concentrations will be measured by a validated bioanalytical method.

Statistical analysis of pharmacokinetic parameters will be based on an ANOVA model. Two-sided 90% confidence interval of the ratio of geometric LSmeans will be obtained from the ln-transformed pharmacokinetic parameters.

Statistical inference of telmisartan will be based on a bioequivalence approach using the following standards:

  • average bioequivalence (the ratio of geometric LSmeans with corresponding 90% confidence interval calculated from the exponential of the difference between the test and the reference product for the ln-transformed parameters Cmax and AUC0-T should all be within the 80.00 to 125.00% bioequivalence range);
  • scaled-average-bioequivalence (in the event that the Cmax reference-to-reference within-subject CV is greater than 30%, that its test-to-reference geometric LSmeans ratio is within the bioequivalence range of 80.00 125.00% and the average bioequivalence criteria are not met, a scaling approach to the bioequivalence assessment will be used).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: In compliance with full replicate design there are two sequences in the study: ABAB and BABA where A = the test product, B = the reference product (see detailed description of items below).
Masking: Single (Outcomes Assessor)
Masking Description: *The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department. Study participants will be aware they will receive different formulations of the same drug, without being informed which product (Test or Reference) is being administered.
Primary Purpose: Other
Official Title: Single Dose, Full Replicate, Crossover Comparative Bioavailability Study of Telmisartan 80 mg Tablets in Healthy Male and Female Volunteers / Fasting State
Actual Study Start Date : September 7, 2018
Actual Primary Completion Date : December 16, 2018
Actual Study Completion Date : December 19, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Telmisartan

Arm Intervention/treatment
Sequence ABAB
Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
Drug: Telmisartan
Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
Other Name: the test product

Drug: Micardis
Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
Other Name: the reference product

Sequence BABA
Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
Drug: Telmisartan
Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
Other Name: the test product

Drug: Micardis
Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
Other Name: the reference product




Primary Outcome Measures :
  1. Cmax of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Maximum concentration in plasma among observed concentrations at pre-specified time points

  2. AUC0-T of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Cumulative area under the concentration time curve calculated from 0 to time of last observed quantifiable concentration


Secondary Outcome Measures :
  1. Tmax of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Time of maximum observed concentration; if it occurs at more than one time point, Tmax is defined as the first time point with this value

  2. TLQC of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Time of last observed quantifiable concentration

  3. AUC0-∞ of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Area under the concentration time curve extrapolated to infinity, calculated as AUC0-T + ĈLQC/λZ, where ĈLQC is the predicted concentration at time TLQC

  4. Residual area of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Extrapolated area (i.e. percentage of AUC0-∞ due to extrapolation from TLQC to infinity)

  5. TLIN of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Time point where the log-linear elimination phase begins

  6. λZ of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Apparent elimination rate constant, estimated by linear regression of the terminal linear portion of the log concentration versus time curve

  7. Thalf of telmisartan for the test and the reference products [ Time Frame: Time points 0.00 (prior to drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 hours after drug administration ]
    Terminal elimination half-life, calculated as ln(2)/λZ


Other Outcome Measures:
  1. Number of treatment-related adverse events (AE) for the test and the reference products [ Time Frame: From the first dosing until 3 days after the collection of the last blood sample of the study ]
    The safety population will include all subjects who received at least one dose of one of the investigational products. All AEs will be graded as mild, moderate, or severe according to the pre-specified definitions. The qualified investigator will determine the relationship of any AE to the study drug using pre-specified criteria (reasonable possibility or no reasonable possibility). Classification of AEs will be performed by System Organ Class (SOC) and Preferred Term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA), version 20.1 or higher.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Provision of signed and dated informed consent form (ICF)
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Healthy male or female adult volunteer
  4. A female volunteer meeting one of the following criteria:

    • (1) Physiological postmenopausal status, defined as the following:

      • absence of menses for at least one year prior to the first study drug administration (not due to amenorrhea secondary to lactation); and
      • Follicle stimulating hormone (FSH) levels ≥ 40 mIU/mL at screening; OR
    • (2) Surgical postmenopausal status, defined as the following:

      • bilateral oophorectomy; and
      • absence of menses for at least 90 days prior to the first study drug administration; and
      • FSH levels ≥ 40 mIU/mL at screening; OR
    • (3) Hysterectomy with FSH levels ≥ 40 mIU/mL at screening

    If the postmenopausal volunteer has an FSH of < 40 mIU/mL, but meets the above criteria in either (1), (2) or (3) and all the other inclusion criteria, the volunteer may be included in the study if the estradiol serum level measured at screening is equal to or below 150 pmol/L. In the case of hysterectomy, if FSH and estradiol do not meet the criteria, inclusion of the volunteer will be based on medical judgment.

  5. Volunteer aged at least 18 years but not older than 55 years
  6. Volunteer with a body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively
  7. Light-, non- or ex-smoker. A light smoker is defined as someone using 10.0 nicotine units or less per day for at least 90 days prior to the first study drug administration. An ex smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration
  8. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without clinical significance, as determined by an investigator
  9. Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an investigator

Exclusion Criteria:

  1. Females who are pregnant according to the pregnancy test at screening
  2. Seated blood pressure below 105/60 mmHg at the screening visit or prior to the first study drug administration
  3. History of significant hypersensitivity to telmisartan or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  4. Presence of significant gastrointestinal, liver or kidney disease, or any other condition known to interfere with drug absorption, distribution, metabolism or excretion, or known to potentiate or predispose to undesired effects
  5. History of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability, including but not limited to cholecystectomy
  6. History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  7. Presence of clinically significant ECG abnormalities at the screening visit, as defined by medical judgment
  8. History of rare hereditary problems of fructose, galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption
  9. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  10. Any clinically significant illness in the 28 days prior to the first study drug administration
  11. Use of any prescription drugs (with the exception of hormone replacement therapy) in the 28 days prior to the first study drug administration, that in the opinion of an investigator would put into question the status of the volunteer as healthy
  12. Any history of tuberculosis
  13. Positive test result for alcohol and/or drugs of abuse at screening or prior to the first drug administration
  14. Positive screening results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAG (B) (hepatitis B)) or Hepatitis C Virus (HCV (C)) tests
  15. Volunteers who have already been included in a previous group for this clinical study
  16. Volunteers who took telmisartan in the 28 days prior to the first study drug administration
  17. Volunteers who took an Investigational Product (IP) in the 28 days prior to the first study drug administration
  18. Volunteers who donated 50 mL or more of blood in the 28 days prior to the first study drug administration
  19. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03705533


Locations
Layout table for location information
Canada, Quebec
Algorithme Pharma, An Altasciences Company
Mount-Royal, Quebec, Canada, H3P 3P1
Sponsors and Collaborators
Pharmtechnology LLC
Algorithme Pharma, An Altasciences Company
Investigators
Layout table for investigator information
Principal Investigator: Eric Sicard, MD Altasciences Company Inc. (doing business as Algorithme Pharma)
Layout table for additonal information
Responsible Party: Pharmtechnology LLC
ClinicalTrials.gov Identifier: NCT03705533    
Other Study ID Numbers: PTL-P3-923
First Posted: October 15, 2018    Key Record Dates
Last Update Posted: December 27, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pharmtechnology LLC:
telmisartan
bioequivalence
Micardis
Additional relevant MeSH terms:
Layout table for MeSH terms
Telmisartan
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action